COVID-19 readmissions during the first three epidemic periods in Orihuela, Spain: incidence, risk factors and letality
e202403023
Keywords:
SARS-CoV-2, COVID-19, Pneumonia, Readmission, PandemicAbstract
BACKGROUND // Readmission for COVID-19 is associated with high mortality, saturation of health services, and high costs. This study aimed to assess the incidence and risk factors of readmissions in COVID-19 patients in a regional hospital of Spain from February 2020 to March 2021.
METHODS // A retrospective cohort study describing the characteristics of adult patients readmitted within thirty days of discharge after being infected with SARS-CoV-2 was carried out. Readmission associated risk factors were analysed using a binary logistic regression model.
RESULTS // Of the 967 patients who survived their first COVID-19 admission, 70 (7.2%) were readmitted within thirty days. Of these, 34.3% presented pneumonia progression, 15.7% functional deterioration, and 12.9% other infections. The mortality rate during readmission was 28.6%. There were no statistically significant differences in the cumulative incidence of readmissions between the epidemic periods (p=0.241). Factors independently associated with readmission were: diabetes mellitus (aOR 1.96, 95%CI 1.07-3.57, p=0.030); acute kidney failure (aOR 2.69, 95%CI 1.43-5.07, p=0.002); not being a candidate for intensive care (aOR 7.68, 95% CI 4.28-13.80, p<0.001); and not being prescribed corticosteroids at discharge (aOR 2.15, 95% CI 1.04-4.44; p=0.039).
CONCLUSIONS // A substantial proportion of patients admitted due to COVID-19 are readmitted, and they carry a high letality. Diabetes mellitus, acute kidney failure, not being a candidate for ICU admission, and not being prescribed corticosteroids on discharge are independently associated with an increased risk of readmission.
Downloads
References
Carvalho T, Krammer F, Iwasaki A. The first 12 months of COVID-19: a timeline of immunological insights. Nat Rev Immunol. 2021;21:245-256.
Khan M, Adil SF, Alkhathlan HZ, Tahir MN, Saif S, Khan M et al. COVID-19: A Global Challenge with Old History, Epidemiology and Progress So Far. Molecules. 2020;26:39.
WHO Coronavirus (COVID-19) Dashboard | WHO Coronavirus (COVID-19) Dashboard With Vaccination Data. [Consultado el 18-04-2023]. Disponible en: https://covid19.who.int/
Loo WK, Hasikin K, Suhaimi A, Yee PL, Teo K, Xia K et al. Systematic Review on COVID-19 Readmission and Risk Factors: Future of Machine Learning in COVID-19 Readmission Studies. Front Public Health. 2022;10.
Vincent J-L, Levi M, Hunt BJ. Prevention and management of thrombosis in hospitalised patients with COVID-19 pneumonia. Lancet Respir Med. 2022;10:214-220.
Taboada M, González M, Alvarez A, Eiras M, Costa J, Álvarez J et al. First, second and third wave of COVID-19. What have we changed in the ICU management of these patients? Journal of Infection. 2021;82:e14-15.
Tyrrell CSB, Mytton OT, Gentry SV, Thomas-Meyer M, Allen JLY, Narula AA et al. Managing intensive care admissions when there are not enough beds during the COVID-19 pandemic: a systematic review. Thorax. 2021;76:302-312.
Soriano V, de Mendoza C, Gómez-Gallego F, Corral O, Barreiro P. Third wave of COVID-19 in Madrid, Spain. International Journal of Infectious Diseases. 2021;107:212-214.
Ramos-Martínez A, Parra-Ramírez LM, Morrás I, Carnevali M, Jiménez-Ibañez L, Rubio-Rivas M et al. Frequency, risk factors, and outcomes of hospital readmissions of COVID-19 patients. Sci Rep. 2021;11:13733.
Wiley Z, Kulshreshtha A, Li D, Kubes J, Kandiah S, Leung S et al. Clinical characteristics and social determinants of health associated with 30-day hospital readmissions of patients with COVID-19. Journal of Investigative Medicine. 2022;70:1406-1415.
Gwin M, Saleki M, Lampert H, Meo N, Bann M. Emergency department visits and readmissions after COVID-19 hospitalization: a cross-sectional analysis. Intern Emerg Med. 2021;16:1715-1718.
Kirkegaard C, Falcó-Roget A, Sánchez-Montalvá A, Valls Á, Clofent D, Campos-Varela I et al. Incidence and risk factors for early readmission after hospitalization for SARS-CoV-2 infection: results from a retrospective cohort study. Infection. 2022;50:371-380.
Akbari A, Fathabadi A, Razmi M, Zarifian A, Amiri M, Ghodsi A et al. Characteristics, risk factors, and outcomes associated with readmission in COVID-19 patients: A systematic review and meta-analysis. Am J Emerg Med. 2022;52:166-173.
Zuil M, Benítez ID, Cabo-Gambín R, Manzano Senra C, Moncusí-Moix A, Gort-Paniello C et al. Clinical management and outcome differences between first and second waves among COVID-19 hospitalized patients: A regional prospective observational cohort. PLoS One. 2021;16:e0258918.
Hennekens CH, Rane M, Solano J, Alter S, Johnson H, Krishnaswamy S et al. Updates on Hydroxychloroquine in Prevention and Treatment of COVID-19. Am J Med. 2022;135:7-9.
Arabi YM, Gordon AC, Derde LPG, Nichol AD, Murthy S, Beidh F et al. Lopinavir-ritonavir and hydroxychloroquine for critically ill patients with COVID-19: REMAP-CAP randomized controlled trial. Intensive Care Med. 2021;47:867-886.
Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, Linsell L et al. Dexamethasone in Hospitalized Patients with Covid-19. New England Journal of Medicine. 2021;384:693-704.
Rodríguez-Baño J, Pachón J, Carratalà J, Ryan P, Jarrín I, Yllescas M et al. Treatment with tocilizumab or corticosteroids for COVID-19 patients with hyperinflammatory state: a multicentre cohort study (SAM-COVID-19). Clinical Microbiology and Infection. 2021;27:244-252.
WHO Solidarity Trial Consortium. Remdesivir and three other drugs for hospitalised patients with COVID-19: final results of the WHO Solidarity randomised trial and updated meta- analyses. Lancet. 2022;399:1941-1953.
Weerakkody S, Arina P, Glenister J, Cottrell S, Boscaini-Gilroy G, Singer M et al. Non-invasive respiratory support in the management of acute COVID-19 pneumonia: considerations for clinical practice and priorities for research. Lancet Respir Med. 2022;10:199-213.
Ramzi ZS. Hospital readmissions and post-discharge all-cause mortality in COVID-19 recovered patients; A systematic review and meta-analysis. Am J Emerg Med. 2022;51:267- 279.
Instituto de Salud Carlos III, Centro Nacional de Epidemiología, Red Nacional de Vilgilancia Epidemiológica. Informe nº 149. Situación de COVID-19 en España. Informe COVID-19. 4 de octubre de 2022. 2022.
Berenguer J, Borobia AM, Ryan P, Rodríguez-Baño J, Bellón JM, Jarrín I et al. Development and validation of a prediction model for 30-day mortality in hospitalised patients with COVID-19: the COVID-19 SEIMC score. Thorax. 2021;76:920-929.
Parra LM, Cantero M, Morrás I, Vallejo-Plaza A, Diego I, Jiménez-Tejero E et al. Hospital Readmissions of Discharged Patients with COVID-19. Int J Gen Med. 2020;Volume 13:1359- 1366.
Verna EC, Landis C, Brown RS, Mospan AR, Crawford JM, Hildebrand JS et al. Factors Associated With Readmission in the United States Following Hospitalization With Coronavirus Disease 2019. Clinical Infectious Diseases. 2022;74:1713-1721.
Finn A, Jindal A, Andrea SB, Selvaraj V, Dapaah-Afriyie K. Association of Treatment with Remdesivir and 30-day Hospital Readmissions in Patients Hospitalized with COVID-19. Am J Med Sci. 2022;363:403-410.
Xu H, Granger BB, Drake CD, Peterson ED, Dupre ME. Effectiveness of Telemedicine Visits in Reducing 30-Day Readmissions Among Patients With Heart Failure During the COVID-19 Pandemic. J Am Heart Assoc. 2022;11.
Nicolás D, Camós-Carreras A, Spencer F, Arenas A, Butori E, Maymó P et al. A Prospective Cohort of SARS-CoV-2-Infected Health Care Workers: Clinical Characteristics, Outcomes, and Follow-up Strategy. Open Forum Infect Dis. 2021;8.
Huang C-W, Desai PP, Wei KK, Liu I-LA, Lee JS, Nguyen HQ. Characteristics of patients discharged and readmitted after COVID-19 hospitalisation within a large integrated health system in the United States. Infect Dis. 2021;53:800-804.
Downloads
Additional Files
- FIGURA 1 (Español (España))
- TABLA 1 (Español (España))
- TABLA 2 (Español (España))
- ANEXO I (a) (Español (España))
- ANEXO I (b) (Español (España))
- ANEXO I (c) (Español (España))
- ANEXO I (d) (Español (España))
- ANEXO I (e) (Español (España))
- ANEXO I (f) (Español (España))
- ANEXO II (a) (Español (España))
- ANEXO II (b) (Español (España))
- ANEXO II (c) (Español (España))
- ANEXO III (Español (España))
- ANEXO IV (Español (España))
- ANEXO V (a) (Español (España))
- ANEXO V (b) (Español (España))
- ANEXO V (c) (Español (España))
- ANEXO V (d) (Español (España))
- ANEXO V (e) (Español (España))
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2024 Nuria Roig-Sánchez, Alberto Talaya Peñalver, Noemí Poveda Ruiz, Alfonso del Pozo, Ana María Hernández Campillo, Alicia Pérez Bernabéu, Belén Martínez-López, Inmaculada González-Cuello, María García-López, Emilio Borrajo Brunete, Philip Wikman-Jorgensen, Jara Llenas-García

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Usted es libre de:
Compartir — copiar y redistribuir el material en cualquier medio o formato.
La licenciante no puede revocar estas libertades en tanto usted siga los términos de la licencia.
Bajo los siguientes términos:
Atribución — Usted debe dar crédito de manera adecuada , brindar un enlace a la licencia, e indicar si se han realizado cambios. Puede hacerlo en cualquier forma razonable, pero no de forma tal que sugiera que usted o su uso tienen el apoyo de la licenciante.
NoComercial — Usted no puede hacer uso del material con propósitos comerciales.
SinDerivadas — Si remezcla, transforma o crea a partir del material, no podrá distribuir el material modificado.
No hay restricciones adicionales — No puede aplicar términos legales ni medidas tecnológicas que restrinjan legalmente a otras a hacer cualquier uso permitido por la licencia.
Avisos:
No tiene que cumplir con la licencia para elementos del material en el dominio público o cuando su uso esté permitido por una excepción o limitación aplicable.
No se dan garantías. La licencia podría no darle todos los permisos que necesita para el uso que tenga previsto. Por ejemplo, otros derechos como publicidad, privacidad, o derechos morales pueden limitar la forma en que utilice el material.